EGF-like module containing mucin-like hormone-like 2 (ERM2) binding agents and methods of use thereof
Anti-EMR2 antibodies and CARs provide targeted therapy for AML by selectively binding to EMR2, enhancing the specificity and efficacy of CAR T-cell therapy for acute myeloid leukemia treatment.
Patent Information
- Application Number
- PCT/US2024/029308
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current therapies for acute myeloid leukemia (AML) lack effective targeted approaches due to the complexity of the disease and the challenge of developing comprehensive treatments, with CAR T-cell therapy showing promise but requiring improved specificity and efficacy.
Development of anti-EMR2 antibodies and chimeric antigen receptors (CARs) that selectively bind to EMR2, utilizing specific amino acid sequences and complementarity determining regions (CDRs) to target EMR2-expressing cells, including hematopoietic malignancies like AML, through monoclonal, humanized, or camelid antibody formats, and their integration into immune cells for therapeutic application.
The anti-EMR2 antibodies and CARs demonstrate selective binding and targeting of EMR2-expressing cells, enhancing therapeutic efficacy in treating AML by specifically engaging immune cells to recognize and attack cancerous cells, thereby improving treatment outcomes for patients with hematopoietic disorders.
Smart Images

Figure US2024029308_21112024_PF_FP_ABST
Abstract
Citation Information
Patent Citations
Introduction and expression of foreign genetic material in epithelial cells
US4868116A
In vivo introduction and expression of foreign genetic material in epithelial cells
US4980286A
Liposomes with enhanced circulation time
US5013556A
Retroviral gene transfer into diploid fibroblasts for gene therapy
US5219740A
Method of testing the dose accuracy of a medication delivery device
US5308341A
Cited By
Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025030010A1
